Pomerantz LLP is investigating Oculis Holding AG and its executives for possible securities fraud following the failure of two Phase 3 trials for its drug OCS-01 targeting diabetic macular edema. The failed trials caused Oculis's stock to drop 23.44% on May 29, 2026. The investigation aims to determine if the company engaged in unlawful practices related to the trial results and stock price impact. Investors affected by the drop are encouraged to contact Pomerantz for potential class action participation.
Zealthy has broadened its insurance coordination program to assist patients prescribed GLP-1 weight-loss medications like Wegovy and Ozempic. The expanded service helps with insurance verification, prior authorizations, and coverage communications, a...
Markets are rallying as investors anticipate potential Federal Reserve rate cuts later in 2026, boosting equities, cryptocurrencies, and other risk assets. QuantRate has introduced a free AI-powered quant trading bot to help retail investors access a...
China's 15th Five-Year Plan (2026-2030) focuses on innovation, resilience, and quality growth, aiming to lead in sectors like quantum computing and 5G. Former EU economist Rudy Aernoudt highlights China's clear, unified long-term planning approach as...
Hypersurface has acquired Acre to create the Hypersurface Bitcoin Premium Income vault (HSBPI), the first fully on-chain Bitcoin volatility trading strategy. This new product allows Bitcoin holders to deposit BTC directly and earn premium income thro...
Muskrat Dam First Nation in northern Ontario was connected to the provincial power grid on April 9, 2026, allowing the community to shut down costly diesel generators. This connection removes previous power constraints, enabling new construction proj...
